Table 1.

Characteristics of randomized clinical trials analyzed.^a

Characteristics	N (%)
Total randomized trials	92
Number of patients -Single agent arm -Combination arm	28,704 13,381 (46.6) 15,323 (53.4)
Total randomized comparisonsb -Phase 2 trial -Phase 3 trial	95 (100) 57 (60) 38 (40)
Types of Randomized Comparisons -Targeted small molecule ± targeted small molecule -Targeted small molecule ± targeted mABs -Targeted small molecule ± immunotherapy -Targeted small molecule ± hormonal -Targeted small molecule ± other -Targeted mABs ± targeted small molecule -Targeted mABs ± targeted mABs -Targeted mABs ± immunotherapy -Immunotherapy ± immunotherapy -Immunotherapy ± not classified -Hormonal agent ± targeted small molecule -Hormonal agent ± targeted mABs -Hormonal agent ± hormonal agent -Hormonal agent ± not classified -Not classifiedc ± targeted small molecule -Not classifiedc ± targeted mABs -Not classifiedc ± hormonal agent	95 19 (20) 11 (11) 2 (2) 1 (1) 1 (1) 9 (9) 3 (3) 2 (2) 7 (7) 3 (3) 22 (23) 5 (5) 5 (5) 2 (2) 1 (1) 1 (1) 1 (1)
Biomarker-based rational for the combination -Yes -No	9 (9) 86 (91)
Tumor Types -Breast -Colorectal -Endometrial -GIST -Head and Neck -Hepatocellular carcinoma -Malignant Mesothelioma -Melanoma -Neuroendocrine -NSCLC -Prostate -Renal cell -Sarcoma -SCLC	95 28 (29) 6 (6) 1 (1) 2 (2) 3 (3) 3 (3) 1 (1) 3 (3) 1 (1) 22 (23) 9 (9) 13 (14) 1 (1) 1 (1)

^aSee Methods for selection criteria.

^bThree trials included to more than one randomized comparison.

^cNot Classified included: prednisone, lenalidomide, cimetidine, retinoic acid, simvastatin, zoledronic acid, alendronate, sargramostim. For a full list of classification of agents see Table 1.

Abbreviations: GIST: gastrointestinal stromal tumor; mAB: monoclonal antibody; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer.